Crossmark

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Crossref DOI link: https://doi.org/10.1038/s41467-021-25901-z

Published Online: 2021-09-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alves, Carla L. https://orcid.org/0000-0003-2266-9349
Ehmsen, Sidse https://orcid.org/0000-0002-4807-6325
Terp, Mikkel G.

Portman, Neil

Tuttolomondo, Martina https://orcid.org/0000-0001-5440-5220
Gammelgaard, Odd L. https://orcid.org/0000-0002-5911-7276
Hundebøl, Monique F.

Kaminska, Kamila

Johansen, Lene E.

Bak, Martin https://orcid.org/0000-0002-6490-2519
Honeth, Gabriella

Bosch, Ana

Lim, Elgene https://orcid.org/0000-0001-8065-8838
Ditzel, Henrik J. https://orcid.org/0000-0003-3927-5135
License Information

Text and Data Mining valid from 2021-09-16

Version of Record valid from 2021-09-16
More Information

Article History

First Online: 16 September 2021